Nomadpharma

nomadpharma.com

Nomad Pharma is a licensed and registered distributor and wholesaler of pharmaceuticals, medical equipment and veterinarian products. Nomad Pharma was founded on the principles of providing high quality pharmaceuticals at affordable prices to its customers. Since its founding Nomad Pharma has grown exponentially, establishing itself as the preferred supplier and partner in the African Pharmaceutical market. We are committed to excellence in all aspects of our business, providing high quality products at competitive rates, yet with a superior service. We source all our products from reputable manufacturers in the EU. our suppliers comply with the latest European GMP (Good Manufacturing Practices) standards and hold ISO certifications.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Pharmacy Market

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Business Insights

GLAUKOS ANNOUNCES MORE THAN 1 MILLION ISTENT® TECHNOLOGIES IMPLANTED WORLDWIDE

Glaukos | September 12, 2022

Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide. This market-leading milestone is a testament to the decades of investment from Glaukos as the corporate founder and pioneer of the now well-established micro-invasive glaucoma ...

JAZZ PHARMACEUTICALS ANNOUNCES NEW RESEARCH COLLABORATION WITH REDX PHARMA TO DISCOVER AND DEVELOP TWO TARGETED CANCER THERAPIES

Jazz Pharmaceuticals | September 09, 2020

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...